|
Brand Name Manufacturers |
Zoladex by Zeneca |
|
Generic Manufacturers |
None |
|
Pharmacology |
GnRH agonist. After an initial stimulating phase, the pituitary
is desensitized to GnRH, which causes it to stop producing
LH, which in turn dramatically decreases gonadal production
of hormones within a month. |
|
Delivery |
Sustained release subcutaneous injection 3.6, 10.8mg |
|
Typical dosage |
Pre-op 3.6mg/month
(3.6mg implant is for 1 month; 10.8 mg implant is for 3 months)
|
|
Availability |
Approved by U.S. FDA |
|
Indications |
Androgen-sensitive prostate cancer |
|
Contraindications |
Known hypersensitivity to GnRH, GnRH analogues, or any of
the components of the product |
|
Adverse reactions |
- CNS
-
Dizziness. Insomnia. Lethargy.
- Gastrointestinal
-
Anorexia. Nausea.
- Skin
-
Sweating.
- Other
-
Congestive heart failure. Fluid retention. Hot flashes.
Increased calcium level in blood. Mild to severe allergic
reactions. Obstructive pulmonary disease. Ureteral and
spinal compression.
|
|
Comments |
None |
| Additional
Info: |
Zoladex
3.6mg Prescribing Information (PDF file on this site)
Zoladex
10.8mg Prescribing Information (PDF file on this site) |